Abstract: An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I): wherein R1 is an unsubstituted or substituted C1 to C8 alkyl group provided that an unsubstituted methyl group is excluded, a C3 to C7 cycloalkyl group, a C6 to C10 bicycloalkyl group or an indanyl group, etc., R2 is a C1 to C4 alkyl group, R3 is a hydrogen atom, a C1 to C5 alkyl group, a C3 to C7 cycloalkyl group, etc., R4 is a hydrogen atom, an unsubstituted or substituted C1 to C5 alkyl group, a halogen atom, etc., R5, R6, R7 and R8 are independently a hydrogen atom, a C1 to C5 alkyl group, etc., X is —(CR11R12)n— or NR13—, wherein n is 0 to 2, R11, R12 and R13 are independently a hydrogen atom, a C1 to C5 alkyl group, etc.

Abstract: An inhibitor against TGF-? expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant alteration of carcinoma in a liver.

Abstract: Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

Abstract: A medicament having an action of inhibiting activation of transcription factor KLF5 and thus inhibiting vascular remodeling and arteriosclerosis, which comprises an acyclic polyprenyl compound (e.g., polyprenylcarboxylic acid such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid and the like) as an active ingredient.

Abstract: A soft capsule preparation which comprises a dispersion of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid in a vegetable oil filled in a soft capsule comprising a shell having a light blocking effect. The soft capsule preparation preferably comprises polyoxyethylene sorbitan monooleate and glycerol monostearate and the like as surfactants. As the vegetable oil, soybean oil, sesame oil, a mixture thereof, or the like may be used.

Abstract: Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.

Abstract: A method for preparing a polyprenyl compound wherein an aldehyde represented by the following general formula [I]: [wherein n represents an integer of from 0 to 3]and a Wittig reagent represented by the following general formula [II]: [wherein each of R1 and R2 represents a group consisting of hydrocarbon] are reacted in a medium as a mixture of water and an organic solvent in the presence of a base, and further in the presence of a crown ether. Said method achieves an excellent selectivity and a high yield.

Abstract: (?)-3-[3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyanilino]-2-methyl-2-cyclopenten-1-one, or its hydrate or solvate, or a pharmaceutical composition containing the same.

Abstract: A method for preparing a polyprenyl compound wherein an aldehyde represented by the following general formula [I]: 1

Abstract: Allyl alcohols are converted into corresponding aldehydes or ketones in a high yield under a mild condition by using an inexpensive aluminum alkoxide as an Oppenauer oxidation catalyst and a hydride acceptor. Thus, there is provided an industrially useful method for converting allyl alcohols to corresponding aldehydes or ketones.

Abstract: Allyl alcohols are converted into corresponding aldehydes or ketones in a high yield under a mild condition by using an inexpensive aluminum alkoxide as an Oppenauer oxidation catalyst and a hydride acceptor. Thus, there is provided an industrially useful method for converting allyl alcohols to corresponding aldehydes or ketones.

Abstract: A method for the storage or transportation of an erythritol by maintaining erythritol in the form of a solution at a concentration and at a temperature in given ranges. Setting up such conditions enables long-term storage of an erythritol solution or transportation of erythritol to the destination in a state of a solution.

Abstract: A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO—B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N—O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antagonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.

Abstract: A process for the preparation of ipidacrine (I) (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinoline) which comprises the reaction of diphosphorus pentaoxide with a trialkyl phosphate and a hydroxyl compound in a hydrocarbon solvent to thereby prepare a polyphosphoric ester having one or more free hydroxyl groups and serving as a dehydrocondensing agent and using this ester without isolation in the condensation of 2-amino-1-cyclopentene-1-carbonitrile with cyclohexanone through dehydration.

Abstract: A theophylline sustained release tablet obtained by coating core granules composed mainly of theophylline with a layer of a coating film composed of a hydrophobic material and a plastic excipient and optionally containing an enteric polymer material to form coated granules and then by compressing the coated granules together with a disintegrating excipient.

Abstract: A method for purification of a polyprenyl compound, which comprises the step of recrystallizing a polyprenyl compound, preferably (2E, 4E, 6E, 10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid by using a solvent comprising an alcohol.

Abstract: A 1,4-dihydropyridine derivative having the formula (I): wherein, R1 represents a substituted or unsubstituted phenyl or pyridyl group, R2 represents a C1 to C5 lower alkyl group, R3 represents a substituted or unsubstituted C1 to C8 alkyl, alkenyl, alkynyl or substituted or unsubstituted C3 to C7 cycloalkyl or cycloalkenyl group, R4 represents —A—R5, wherein A represents a C3 to C5 alkynylene group having one triple bond, and R5 represents a substituted or unsubstituted pyridyl, quinolyl, isoquinolyl or pyrimidyl group and a drug for overcoming resistance to an anti-cancer drug or a drug increasing the effect of an anti-cancer drug containing as an effective ingredient the derivative or its pharmacologically acceptable salt or hydrate.

Abstract: A novel N-hydroxyurea derivative represented by formula (I) and having antiallergic and anti-inflammatory effects, i.e., N-hydroxy-N-[6-(3-pyridylmethyl)-2H-1-benzopyran-3-ylmethyl]urea: and medicines containing the above urea derivative or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof as the active ingredient, particularly antiallergic or anti-inflammatory agent, especially antiasthmatic.

Abstract: A cation exchange resin preparation in the dosage form of dry syrups and the like which comprises a cation exchange resin such as polystyrene calcium sulfonate and a gelleing agent such as carboxymethylcellulose sodium (CMC-Na), and may further comprises a binder such as hydroxypropyl cellulose (HPC). The preparation gelates and/or swells without disintegration for a few tens seconds to a minute or so when taken as suspensions in water or the preparation, per se. Therefore, the sandy feel in the mouth and throat, which is a problem in taking the preparation comprising a cation exchange resin alone, is reduced and the taste and easiness in oral administration are both improved.

Abstract: A 2-phenylmorpholin-5-one derivative having the formula (I): wherein R1 represents a C1 to C8 alkyl group, a C3 to C7 cycloalkyl group or an indanyl group, R2 represents a C1 to C4 alkyl group, R3 represents a hydrogen atom, a C1 to C5 alkyl group, etc., R4 represents a hydrogen atom, a C1 to C6 alkyl group, etc., R5, R6 represent a hydrogen atom, a C1 to C5 alkyl group, etc., an optical isomer thereof or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof and a pharmaceutical composition containing the same. The above compound has a strong type IV phosphodiesterase (PDE) inhibitory activity and has bronchodilater and antiinflammatory effects.